Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Samarium 153Sm lexidronam

H M Lamb1, D Faulds

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs & Aging
|November 14, 1997
PubMed
Summary
This summary is machine-generated.

Samarium 153Sm lexidronam effectively relieves pain in patients with bone metastases. This radiopharmaceutical demonstrated significant pain reduction and acceptable toxicity, offering a new therapeutic option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

131I tositumomab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Cladribine: a review of its use in multiple sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Mizolastine: a review of its use in allergic rhinitis and chronic idiopathic urticaria.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Denileukin diftitox.

American journal of clinical dermatology·2001
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
Same journal

Adapting the Geriatric Medicine 5Ms Framework to Geriatric Dermatology.

Drugs & aging·2026
Same journal

External Validation of a Community Pharmacy-Based Screening Tool for Frailty That Uses Routinely Collected Data.

Drugs & aging·2026
See all related articles

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmacology

Background:

  • Bone metastases cause significant pain and reduced quality of life in cancer patients.
  • Current treatments for bone pain may have limited efficacy or significant side effects.

Purpose of the Study:

  • To evaluate the efficacy and safety of Samarium 153Sm lexidronam for managing pain associated with bone metastases.

Main Methods:

  • A randomized, placebo-controlled trial was conducted.
  • Patients received either Samarium 153Sm lexidronam (1 mCi/kg) or placebo.
  • Pain relief, duration, and toxicity were assessed.

Main Results:

  • 72% of patients receiving Samarium 153Sm lexidronam experienced pain relief compared to 44% in the placebo group (p < 0.025).

Related Experiment Videos

  • Pain relief was achieved within 2 weeks and lasted a median of 8-15 weeks.
  • The primary dose-limiting toxicity was reversible myelosuppression.

    • Conclusions:

    • Samarium 153Sm lexidronam is an effective agent for pain palliation in patients with bone metastases.
    • The treatment offers a favorable safety profile with manageable toxicity.
    • Repeat dosing may provide further pain relief in some patients.